Measurable residual disease in haematological and solid cancers

Roland B Walter^{1

2

3}, Robert Peter Gale⁴

Affiliations

¹ Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. rwalter@fredhutch.org.
² Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
⁴ Imperial College London, London, UK.

Editorial

Roland B Walter et al. Leukemia. 2024 Aug.

. 2024 Aug;38(8):1647-1648.

doi: 10.1038/s41375-024-02295-7. Epub 2024 Jun 27.

Roland B Walter^{1

2

3}, Robert Peter Gale⁴

¹ Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. rwalter@fredhutch.org.
² Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
³ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
⁴ Imperial College London, London, UK.

No abstract available

References

1. Goldman JM, Gale RP. What does MRD in leukemia really mean? Leukemia. 2014;28:1131. - DOI - PubMed
1. Ofran Y, Rowe JM. Cytogenetics or MRD in B-cell ALL. Do both reign supreme? Leukemia. 2022;36:1201–2. - DOI - PubMed
1. Del Giudice I, Foà R. Measurable residual disease in chronic lymphocytic leukemia. Where do we stand? Leukemia. 2023;37:2339–42. - DOI - PubMed
1. Walter RB. Perspective on measurable residual disease testing in acute myeloid leukemia. Leukemia. 2024;38:10–13. - DOI - PubMed
1. Chen J, Gale RP, Hu Y, Yan W, Wang T, Zhang W. Measurable residual disease (MRD)-testing in haematological and solid cancers. Leukemia 2024; in press.